ChartTrends®: Renal Anemia in CKD-ND (US)
An annual report providing patient level chart audit data to give insights into the management of renal anemia in chronic kidney disease non-dialysis (CKD-ND) patients
Study Overview:
ChartTrends are syndicated reports designed to compare what physicians self-report about disease management to what actually occurs at the patient level. Through an in-depth review of specific patient charts, details such as product dosing and titration, switching, concomitant medications, and a host of laboratory and patient demographic variables help define patient types and identify therapy triggers. The report will capture patient level data from 1000 unique later stage (Stage 3/4/5 not on dialysis) CKD patient records. The data will be used to quantify the CKD-ND population and understand the treatment prevalence of and prescribing drivers for erythropoiesis stimulating agents (ESAs), oral iron, and IV iron in this patient population. This will be the 5thwave of the ChartTrends: Renal Anemia in CKD-ND (US) report.
Methodology:
Each nephrologist will complete a brief demographic, self-reported treatment prevalence, and attitudinal position profile upon registering to participate in the research. Nephrologists will then complete 3-6 audits, for a total of 1000 audits, from later stage (Stage 3/4/5) CKD patient charts. All methods are HIPAA compliant.
Sample Frame:
The report will include responses from a random sample of 200-250 nephrologists providing information on 1,000 unique CKD-ND patients. Patient charts must be from patients who are at least 18 years of age and have Stage 3, 4, or 5 CKD-ND.
Timing:
This report is fielded and published annually. The final report will be delivered on September 30th.
Deliverables:
In addition to the final report, a complete set of frequency tables, summary statistics, and cross-tabulations will be provided. Clients will also receive the patient database in SPSS. Onsite or web-cast presentations are available upon request at no charge.
